KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuances
Ratios

Abbott Laboratories (ABT) Long-Term Debt Repayments (2016 - 2026)

Abbott Laboratories' Long-Term Debt Repayments history spans 15 years, with the latest figure at $1.4 billion for Q1 2026.

  • On a quarterly basis, Long-Term Debt Repayments rose 41.46% to $1.4 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $2.9 billion, a 185.9% increase, with the full-year FY2021 number at $48.0 million, down 96.4% from a year prior.
  • Long-Term Debt Repayments hit $1.4 billion in Q1 2026 for Abbott Laboratories, up from $501.0 million in the prior quarter.
  • Over the last five years, Long-Term Debt Repayments for ABT hit a ceiling of $1.4 billion in Q3 2023 and a floor of $1.0 million in Q2 2022.
  • Historically, Long-Term Debt Repayments has averaged $467.2 million across 5 years, with a median of $18.0 million in 2024.
  • Biggest five-year swings in Long-Term Debt Repayments: soared 144400.0% in 2023 and later crashed 99.86% in 2024.
  • Tracing ABT's Long-Term Debt Repayments over 5 years: stood at $1.0 million in 2022, then soared by 144400.0% to $1.4 billion in 2023, then crashed by 99.86% to $2.0 million in 2024, then surged by 24950.0% to $501.0 million in 2025, then soared by 182.63% to $1.4 billion in 2026.
  • Business Quant data shows Long-Term Debt Repayments for ABT at $1.4 billion in Q1 2026, $501.0 million in Q3 2025, and $1.0 million in Q2 2025.